EMYRIA ORD
Emyria Commences Empax PTSD Care Program at Perth Clinic and Launches Interstate Expansion
Emyria (ASX: EMD) has begun delivering its Empax therapy for post-traumatic stress disorder (PTSD) at a Perth clinic under Australia’s first private health insurance program for psychedelic-assisted treatment. Medibank Private (ASX: MPL) is funding the program under an initial two-year agreement secured in June and will make it available to eligible health fund members. The […]
Emyria’s Empax PTSD trauma care program gains funding support from Medibank Private
Health insurer Medibank Private (ASX: MPL) has commenced funding for eligible members to access the Empax post-traumatic stress disorder (PTSD) care program developed by Emyria (ASX: EMD) and Perth Clinic. The initial two-year agreement marks the first major private health insurance funding of a psychotherapy-led PTSD program in Australia and Emyria regards the move as […]
Emyria and University of Western Australia to research MDMA compounds for treatment of mental health disorders
Clinical drug development and care delivery company Emyria (ASX: EMD) has entered into an agreement with the University of Western Australia (UWA) to examine and expand a unique library of proprietary MDMA-like compounds (or ‘analogues’) developed over the last 10 years. The agreement is considered an important step in investigating the potential of MDMA analogues […]
Emerald Clinics signs cannabis RWE contract with Canopy Growth’s UK subsidiary Spectrum Biomedical
Real-world evidence company Emerald Clinics (ASX: EMD) has hauled in a significant new client in the form of Spectrum Biomedical UK (SBUK), the UK-based subsidiary of the world’s largest cannabis company Canopy Growth, to develop a real-world evidence (RWE) system in the UK. The agreement supplements an existing relationship Emerald has established with Spectrum Therapeutics, […]
